Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 13/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 12/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7324340 | 0.84 | ALDH1A1 (0.61) | MTNR1BMTNR1ACES2CES1LMNA | |
| SCHEMBL9423504 | 0.83 | LMNA (0.56) | MTNR1BMTNR1ACES2CES1LMNA | |
| SCHEMBL7852386 | 0.82 | KMT2A (0.53) | MTNR1BMTNR1ALMNATSHRALDH1A1 | |
| SCHEMBL8129033 | 0.80 | MTNR1B (0.49) | MTNR1BMTNR1ACES2CES1LMNA | |
| SCHEMBL8395078 | 0.79 | LMNA (0.51) | MTNR1BMTNR1ACES2CES1LMNA | |
| SCHEMBL8017865 | 0.78 | KDM4E (0.54) | MTNR1BMTNR1ALMNATSHRALDH1A1 | |
| SCHEMBL7694497 | 0.77 | ALDH1A1 (0.57) | MTNR1BMTNR1ACES2CES1LMNA | |
| SCHEMBL13135118 | 0.77 | MTNR1B (0.57) | MTNR1BMTNR1ACES2CES1LMNA | |
| SCHEMBL8455849 | 0.76 | L3MBTL1 (0.54) | MTNR1BMTNR1ACES2CES1THRB | |
| 1,3-Dimethoxybenzene SCHEMBL28097323 | 0.76 | PARP1 (0.66) | MTNR1BMTNR1ACES2CES1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322624-B1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-21 | — | — | EP | disclosed |
| US-7091201-B2 | Arylalkane-sulfonamides having endothelin-antagonist activity | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-15 | — | — | US | disclosed |
| US-20040102464-A1 | Arylalkane-sulfonamides having endothelin-antagonist activity | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-05-27 | — | — | US | disclosed |
| EP-1322624-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | Actelion Pharmaceuticals Ltd. (CH) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002083650-A1 | NOVEL SULFONYLAMINO-PYRIMIDINES | ACTELION PHARMACEUTICALS LTD (CH) | 2002-10-24 | — | — | WO | disclosed |
| EP-0768304-B1 | N-(Pyrimidinyl)-benzenesulfonamides as medicaments | HOFFMANN LA ROCHE (CH) | 2002-05-22 | — | — | EP | disclosed |
| WO-2002024665-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2002-03-28 | — | — | WO | disclosed |
| WO-2001081338-A1 | SUBSTITUTED SULFONYLAMINOPYRIMIDINES | ACTELION PHARMACEUTICALS LTD (CH) | 2001-11-01 | — | — | WO | disclosed |
| EP-0526708-B1 | Sulfonamide, preparation and use thereof as medicine and intermediate | HOFFMANN LA ROCHE (CH) | 2000-10-18 | — | — | EP | disclosed |
| EP-0768304-A1 | N-(Pyrimidinyl)-benzenesulfonamides as medicaments | F. HOFFMANN-LA ROCHE AG (CH) | 1997-04-16 | — | — | EP | disclosed |
| EP-0526708-A1 | Sulfonamide, preparation and use thereof as medicine and intermediate | F. HOFFMANN-LA ROCHE AG (CH) | 1993-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102464-A1 | Arylalkane-sulfonamides having endothelin-antagonist activity | EDNRA, EDNRB, ECE2 | MTNR1B 707/4885MTNR1A 876/4885CES2 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.